This Wednesday, October 16, 2024, during the question session to the government, the senator from Calvados Corinne Féret (PS) questioned the Minister of the Economy, Antoine Armand, about the sale by the Sanofi group of its subsidiary Opella, producer of Doliprane, to an American investment fund (CD & R).
The elected official recalled her “firm opposition” to this sale and asked the minister to prevent it.
“This sale poses serious health sovereignty issues and constitutes a direct threat to the 1,700 jobs linked to the industrial and commercial activity of Opella in France, 250 employees in Lisieux,” explains the senator. She continues: “The Montebourg decree allows the government to veto the takeover of any company whose activities are essential to guaranteeing the protection of the public health of the French. Doliprane, an essential medicine for millions of French people, must not change nationality! »
“Take into account the lessons of Covid”
Already on Tuesday, the subject was invited into the debates in the National Assembly. Joël Bruneau, former mayor of Caen now a deputy, called for “take into account the lessons of the Covid crisis by preserving our industrial sovereignty over the manufacture of medicines” . He asks the government to “oppose the sale of the Sanofi subsidiary to a foreign group, even though there seem to be potential French buyers” .
As a reminder, the CGT and CFDT of Sanofi are calling for a renewable strike starting Thursday, October 17, to protest against this proposed sale.
France
